The United States represents a major market for microbiome drugs in North America, supported by strong pharmaceutical and biotechnology research capabilities. Rising investments in drug development, increasing clinical studies, and growing interest in microbiome-based treatments for gastrointestinal and metabolic disorders are driving market expansion. Favorable research initiatives and...